Reports revenue $21.5M, consensus $20.83M. “Our strong fourth quarter performance reflects our continued progress in establishing Focal One ...

Our strong fourth quarter performance reflects our continued progress in establishing Focal One Robotic HIFU as a mainstream treatment option for the management of prostate cancer,” said Ryan Rhodes, ...

AUSTIN, Texas, March 27, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, reported today unaudited consolidated financial results for the fourth quarter and full ...

Approval was based on findings from the pivotal CABINET trial showing improved PFS and response rates vs placebo.

In the latest installment of Healio’s video series with ASGE, Fiyinfoluwa O. Abraham, MD, discusses ethnic and racial disparities observed in the incidence of pancreatic cancer, demonstrating the need ...

The warning comes as experts battle to understand a disturbing rise in bowel cancers in under 50s in the UK and the US.